Targeting macrophages is a promising strategy for improved therapy of intracellular infections as macrophages exhibit rapid phagocytosis of particles >200 nm. Entrapment of Curcumin (CUR) in nanocarriers could provide bioenhancement and macrophage targeting. We present a simple and facile in situ nanoprecipitation approach for instantaneous and on-site generation of curcumin nanoparticles (ISCurNP). ISCurNP optimised by Box-Behnken design exhibited average size of 208.25 AE 7.55 nm and entrapment efficiency of 90.16 AE 1.17%. Differential scanning calorimetry and X-Ray diffraction confirmed amorphization of CUR in ISCurNP. Sustained release was observed over 72 hr in vitro at lysosomal pH 4.5. Rapid and high uptake in RAW 264.7 macrophages was confirmed by flow cytometry and high performance liquid chromatography. Confocal microscopy established localisation of ISCurNP in lysosomal compartment. The facile in situ nanoprecipitation method provides simple, scalable technology to enable macrophage targeted delivery of CUR, with great promise for improved therapy of intracellular infections.
| INTRODUCTION
Curcumin (CUR), a natural polyphenol has generated tremendous excitement as a nutraceutical due to its multifarious pharmacological activities. 1, 2 The anticancer [3] [4] [5] [6] and anti-inflammatory 7, 8 properties of CUR have been widely explored. CUR, an established anti-infective for eons, is currently being extensively researched for antibacterial including antimycobacterial, antiviral, and antifungal activity. [9] [10] [11] Despite the excellent therapeutic potential, a considerable impediment in exploitation of CUR as a therapeutic agent is its hydrophobic nature and consequently poor aqueous solubility. 12 Nanonization of particles has proven to be a competent approach to enhance solubility and bioavailability of hydrophobic poorly soluble drugs. 13, 14 Furthermore, such drugs when entrapped in nanocarriers with size titrated in the range of 200-600 nm can aid targeting to the reticuloendothelial system (RES) organs and cells, especially macrophages, the primary site of various intracellular infections. [15] [16] [17] [18] Macrophages constitute defense system of the body and exhibit rapid phagocytosis of particles >200 nm. Targeting the macrophages by nanocarriers thus provides a viable approach to restrict growth and survival of the organisms.
Conventional nanotechnology approaches are based on multiple steps and dictate the need for sophisticated equipment. Furthermore, isolation of nanoparticles (NPs) prepared and their stabilization by freeze drying also pose significant scale-up challenges, constituting major hurdles in the development and translation of nano drug delivery systems. 19 In contrast, in situ nanotechnology presents a method wherein generation of NPs is achieved by simple addition of a monophasic preconcentrate comprising drug, carrier (polymer/lipid), and stabilizers to an aqueous phase. Our group has reported in situ nanotechnology as a facile method for instantaneous and on-site generation of NPs to enable point of care application. [20] [21] [22] A distinct advantage of in situ technology is total bypass of the technological hurdles and stability issues associated with conventional NP fabrication methods. First generation in situ nanotechnology relies on dilution of monophasic preconcentrates with an aqueous media like potable drinking water just prior to oral administration or dextrose/ dextrose saline injection just prior to intravenous injection. Enhanced oral bioavailability was demonstrated from a self nanoprecipitating preconcentrate of tamoxifen citrate, which on dilution with aqueous media resulted in the formation of polymeric tamoxifen NPs with 85% entrapment efficiency and average particle size <250 nm. 20 An in situ hybrid nanoparticulate drug delivery system of nevirapine designed for simultaneous targeting of multiple reservoirs in HIV exhibited >90% drug entrapment in a mixture of solid lipid NPs and micelles which was instantaneously generated when the preconcen- 
| ISCurNP
Preconcentrates were added to filtered distilled water for instantaneous formation ISCurNP. The RP HPLC method was validated for linearity, accuracy, and precision.
| Stability
Preconcentrate was evaluated for stability as per International Conference on Harmonization (ICH) guidelines. Preconcentrate was packed in amber colored glass vials flushed with nitrogen and stored at 30 AE 2 C/65 AE 5% RH and 40 AE 2 C/75 AE 5% RH. At prescribed time intervals, preconcentrate was evaluated for drug content.
At the same time intervals, ISCurNP was generated from the preconcentrate as described in 2.3.2 and evaluated for particle size and entrapment efficiency as described below.
| Evaluation of ISCurNP
The preconcentrate was diluted with aqueous medium to generate ISCurNP which were evaluated as below:
| Particle size and zeta potential
Particle size (PS), polydispersity index (PDI) and zeta potential measurements of ISCurNP were evaluated on Nano Brook 90 Plus PALS (Brookhaven Instruments, NY, USA). Size distribution was determined by dynamic light scattering (DLS) at 25 C. Zeta potential measurements were carried out using phase analytical light scattering (PALS). ISCurNP was suitably diluted with filtered distilled water and measurements were recorded in triplicate.
| Entrapment efficiency
The ISCurNP generated was centrifuged at 16,350 rcf for 20 min at 20 C. Aliquot (1 ml) was carefully withdrawn from the supernatant, diluted to 10 ml with methanol and CUR concentration was estimated by UV spectrophotometry at λ max 425 nm. EE was calculated using the equation below:
| Particle imaging
Scanning electron microscopy For scanning electron microscopy (SEM) analysis, a drop of ISCurNP was placed on a piece of aluminium foil mounted on carbon tube and air dried. Prior to analysis, sample was sputtered with platinum using an auto fine coater. Samples were analyzed using FEI Quanta 200 SEM with EDS.
Transmission electron microscopy
Transmission electron microscopy (TEM) analysis was performed using TECNAI 12 BT/FEI TEM at 120 kV. Briefly, a drop of ISCurNP was placed on carbon grid (Ted Pella, Inc., Redding) and air-dried followed by negative staining with 2% uranyl acetate.
Following size and entrapment evaluation, ISCurNP dispersion was centrifuged, the pellet washed and redispersed in filtered distilled water and lyophilized using LABCONCO freeze dryer (FreeZone 4.5).
This freeze-dried solid sample was utilized for Differential scanning calorimetry (DSC), powder X-ray diffraction (XRD) and Fouriertransform infrared spectroscopy (FTIR) evaluation.
| Differential scanning calorimetry
DSC was performed under nitrogen purge (20 ml/min) using Perkin Elmer Pyris 6 DSC instrument (PerkinElmer, Netherlands). Thermograms were recorded by sealing samples (5 mg) in aluminium pans followed by heating over the temperature range 40-300 C at rate of 10 C/min. Empty sealed aluminium pan served as reference.
| Powder X-ray diffraction
X-ray diffraction spectra were recorded on Bruker X-ray diffractometer under ambient conditions. Instrument was operated at 40 kV voltage and 40 mA current at 2θ/min scanning speed, scanning angles from 5 to 70 (2θ) with a 0.2 step size.
| Fourier-transform infrared spectroscopy
Samples were prepared in the form of KBr pellets and scanned from 3800 to 400 cm −1 using FTIR spectrophotometer (Perkin-Elmer, Model Spectrum Two). A scan with blank KBr pellet eliminated background interference.
| Effect of dilution volume
Preconcentrate (0.75 ml) was maintained constant while the aqueous dilution volume was varied from 5-250 ml. The ISCurNP generated was evaluated for PS and EE.
| In vitro release
Release of CUR from NPs was evaluated by a modified dialysis method. ISCurNP dispersion (5 ml) and free CUR suspended in 1% sodium lauryl sulfate (SLS) solution (5 ml) equivalent to 5 mg CUR were loaded into activated dialysis bags (Himedia 12-14 kDa molecular weight cut-off ). The dialysis bags were then introduced into the basket of USP dissolution apparatus I and immersed in 500 ml of dissolution medium maintained at 37 AE 0.5 C. The rotation speed was 100 rpm. Physiological buffer solution pH 1.2 and pH 6.8 and artificial lysosomal fluid pH 4.5 (composition in Supporting Information Table S2 ), supplemented with 1% SLS were used as dissolution medium (500 ml). Aliquots (5 ml) were withdrawn at specific time intervals and estimated at λ max of 425 nm by UV spectroscopy to quantify the amount of CUR released. Graphs of cumulative percent drug release versus time were plotted.
| Cells
RAW 264.7 murine macrophage cell line was procured from American
Type Culture Collection and grown in Dulbecco's modified eagle medium (DMEM) supplemented with 10% heat inactivated fetal bovine serum (FBS) and 1% penicillin/streptomycin at 37 C in a humidified incubator with 5% CO 2 until confluent. Cells were used from 3 to 12 passages.
| Sample preparation
Sterile preconcentrate was prepared by filtration through sterile 0.22 μm membrane filters under aseptic conditions. ISCurNP was generated by addition of 0.75 ml sterile preconcentrate to sterile distilled water to obtain CUR concentration 1 mg/ml. CUR stock was prepared by dissolving free CUR in cell culture grade dimethyl sulfoxide (DMSO) (5 mg/ml). All the concentrations were considered in μM corresponding to the total amount of CUR incorporated. Final dilutions were prepared in DMEM supplemented with 5% FBS. In situ generated Blank NP and DMSO served as controls.
| Stability of ISCurNP in culture medium
Aliquots of ISCurNP (equivalent to 100 μM) in DMEM, were placed in Eppendorf tubes and incubated at 37 C and PS was recorded at 0, 3, 5, 24, 48, and 72 hr, using the Nano Brook 90 Plus Zeta instrument. 
| Cell viability assay

| Macrophage uptake
Uptake of ISCurNP in the macrophages was evaluated flow cytometry, confocal microscopy and reverse phase HPLC.
| Flow cytometry
Cells ( 
| Statistical analysis
All experimental results are expressed as mean AE standard deviation of minimum three independent measurements. Student's t-test was applied for statistical analysis and p < .05 has been considered as statistically significant.
| RESULTS AND DISCUSSION
| Fabrication and optimization of nanoparticles
A prerequisite for in situ nano drug delivery system is a pharmaceutically acceptable water miscible solvent that can solubilize the drug and excipients. While CUR exhibited limited solubility in most solvents, maximum and high solubility was observed in DMA (Supporting Information Figure S1 ).
Design of experiment-based approaches can assess single variables as well as interactions between different variables, enabling
optimization with fewer experiments, resulting in improved efficiency. [27] [28] [29] Two-level designs like full or fractional factorial design provide restricted statistical outputs. Among the response surface designs, which are based on more than two-factor levels, the most efficient and widely used design is the three-level Box-Behnken design. [30] [31] [32] In this design, a midpoint of each side of a multidimensional cube is selected and set of points around these are chosen whereby extreme values are avoided. Furthermore, interactions between the independent variables are also accounted for.
The desired levels of the dependent variables were average PS The surface plots ( Figure 1 Three test compositions ISCurNP1, ISCurNP2, and ISCurNP3 were generated using the design and the dependent variables predicted (Table 1 ). The actual data generated for these compositions closely ISCurNP2 was considered as the optimized batch and selected for further studies. Figure S2 ).
| Evaluation of preconcentrate
The disappearance of the peaks characteristic of crystalline CUR in the XRD spectra also confirmed amorphization of CUR (Supporting Information Figure S3 ).
FTIR spectra of ISCurNP (Supporting Information Figure S4) depicted presence of C=O stretch at 1,625 and 1,762 cm Particle imaging: (a) SEM micrograph, (b) TEM micrograph, and (c) particle size distribution of ISCurNP corresponding to carbonyl groups in CUR and PLGA respectively. NPs, due to their small size, large surface area, and surface properties are prone to aggregation. Although there was good stability up to 24 hr as indicated by PS, small aggregates were seen after 6 hr. Nevertheless, these aggregates could be readily redispersed by mild shaking and revealed good stability when monitored on PS analyzer, suggesting formation of floccules. As ISCurNP is designed for immediate administration, even 6 hr stability was considered more than adequate.
During the optimization study, dilution volume was maintained constant at 10 ml. When injected, dilution would be carried out by trained health professionals and hence a dilution volume may be prescribed. However, when administered orally the dilution would be carried out by untrained users. To understand the ruggedness under such conditions of use, we evaluated the effect of varying the dilution volume on PS and EE (Supporting Information Figure S5 ). ISCurNP revealed no significant change in PS and EE when the dilution volume was varied from 10 ml (two teaspoons) to 100 ml (about half a glassful; p > .05). At 5 ml faster aggregation was seen. However, a 3 hr stability was observed which was considered satisfactory. At >100 ml, a significant decrease in PS was observed (p < .05). Although considered rugged to dilution, as a consideration in translation a measuring cup of about 50-75 ml may be provided to ensure dilution volume within the desirable range.
In vitro release
In vitro release of ISCurNP was studied at pH 1.2 and pH 6.8 to mimic the pH in the stomach and intestine, respectively. At pH 1.2, no release was observed upto 2 hr from ISCurNP suggesting that the NPs would remain intact in the stomach. However, at pH 6.8 sustained release of CUR from ISCurNP was observed upto 24 hr with maximum 46.6% release while free CUR demonstrated of 28.09% release (Supporting Information Figure S6 ). We have previously observed that hydrophilic NPs show gastric tropism 34 while hydrophobic NPs favor intestinal accumulation 35 . Such intestinal accumulation could favor high uptake of intact NPs through M cells of Peyer's patches followed by translocation through the lymph into systemic circulation. 29 In an analogous manner, we hypothesize that ISCurNP being hydrophobic could exhibit intact NP uptake through Peyer's patches, and translocate through lymph to systemic circulation to favor macrophage uptake. Release was also evaluated in artificial lysosomal fluid pH 4.5 to simulate the environment in the macrophages.
NPs revealed 76.29 AE 3.5% release of CUR from ISCurNP at 72 hr, suggesting slow but near complete release (Figure 3 ). Model fitting revealed CUR release from ISCurNP followed Higuchi model at both pH 4.5 and 6.8 (Supporting Information Table S5 ).
Stability in culture medium
Biological media components could adsorb onto NPs to alter their surface characteristics and lead to aggregation. Such aggregated NPs can alter the cellular uptake, cytotoxicity or even the in vivo fate. 36 Physical stability (size) of NPs in cell culture medium was evaluated to ensure that they do not aggregate and remain discrete when evaluated in cell lines. No significant change in PS was seen upto 48 hr (p > .05). At 72 hr, although the size increased, the average size of <400 nm was considered acceptable (Supporting Information Figure S7 ).
Cell viability assay
MTT assay is widely used for assessing cytotoxicity in cell lines. MTT 
| Macrophage uptake
Macrophages rapidly engulf and internalize all foreign invasions including organisms and particles by phagocytosis. 38 Typically, hydrophobic particles are taken up by this pathway. 39, 40 Phagocytosis results in trapping of the foreign invasion in a phagosome which coalesce with the lysosomes present in the macrophages to form phagolysosomes. The harsh phagolysosomal environment which has a low pH and lysosomal enzymes results in degradation/killing of the internalized organism. However, organisms that have mastered the art of phagosomal survival can competently arrest early phagosome maturation and hinder phagolysosome fusion. 41 The phagosome provides a safe sanctuary for such organisms. Given time, some of these organisms can also generate a protective resistant shield as in case of Mycobacterium tuberculosis. 42 Elimination of such intracellular infections poses significant challenges dictating the need for intracellular delivery of the drug at therapeutic concentration. 18, 43, 44 Nanocarrierbased delivery is an effective strategy for high intracellular delivery, nevertheless yet another challenge is to ensure that the drug from the nanocarrier is released out of the phagolysosome into the cytoplasmic compartment which harbors the organisms. In the present study, we monitored ISCurNP uptake and also quantified CUR concentration in the RAW 264.7 macrophage cell line.
Flow cytometry analysis relied on fluorescence emission of CUR.
The concentration and time dependent uptake of CUR is depicted in Figure 5 . Both free CUR and ISCurNP revealed time dependent increase in uptake at both concentrations (p < .05). Significant uptake at 1 hr confirmed rapid internalization of ISCurNP. Further, uptake exhibited by ISCurNP was significantly higher than free CUR (p < .05).
At 3 hr, while increase in CUR concentration from 10 to 20 μM revealed approximate twofold increase, this increase was approximately threefold when the ISCurNP concentration was similarly increased.
Uptake of ISCurNP by macrophages was also monitored by confocal microscopy to understand intracellular trafficking ( Figure 6 ). As results confirmed 93% co-localization with the lysosomal markers. 45 We monitored the subcellular localization of NPs using Lyso Tracker™
Red and DAPI which localize in the lysosomes and nucleus respectively ( Figure 7 
| CONCLUSION
In situ nanoprecipitation presents a facile approach for development of polymeric curcumin NPs. The low cytotoxicity and high uptake of ISCurNP in the RAW 264.7 cells confirms macrophage targeting and potential application in the therapy of intracellular infections. Based on technology that is simple and scalable, ISCurNP presents a targeted nanocarrier system with ease of translation from bench to clinic.
